<?xml version="1.0" encoding="UTF-8"?>
<!--Generated by Squarespace Site Server v5.11.81 (http://www.squarespace.com/) on Sun, 27 May 2012 16:41:18 GMT--><feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/"><title>Press Releases</title><subtitle>Press Releases</subtitle><id>http://www.sunshineheart.com/press-releases/</id><link rel="alternate" type="application/xhtml+xml" href="http://www.sunshineheart.com/press-releases/"/><link rel="self" type="application/atom+xml" href="http://www.sunshineheart.com/press-releases/atom.xml"/><updated>2012-03-15T15:59:22Z</updated><generator uri="http://www.squarespace.com/" version="Squarespace Site Server v5.11.81 (http://www.squarespace.com/)">Squarespace</generator><entry><title>Sunshine Heart Announces FDA Completes Review of C-Pulse® Feasibility Data</title><id>http://www.sunshineheart.com/press-releases/sunshine-heart-announces-fda-completes-review-of-c-pulse-fea.html</id><link rel="alternate" type="text/html" href="http://www.sunshineheart.com/press-releases/sunshine-heart-announces-fda-completes-review-of-c-pulse-fea.html"/><author><name>Sunshine Heart</name></author><published>2012-03-15T15:55:50Z</published><updated>2012-03-15T15:55:50Z</updated><summary type="html" xml:lang="en-US"><![CDATA[Sunshine Heart, Inc. (NASDAQ: SSH, ASX: SHC) today announced that the Center for Devices and Radiological Health(CDRH) of the United States Food and Drug Administration(FDA) completed its review of Sunshine Heart’s Investigation Device Exemption(IDE) for the C-Pulse Heart Assist System feasibility trial. The FDA notified the Company that it has met the requirements of FDA regulation 21CFR 812.150(b)(5) and that no other information is required at this time.]]></summary></entry><entry><title>Sunshine Heart Announces Results of its C-Pulse® Feasibility Trial at the Transcatheter Cardiovascular Therapeutics Conference</title><id>http://www.sunshineheart.com/press-releases/sunshine-heart-announces-results-of-its-c-pulse-feasibility.html</id><link rel="alternate" type="text/html" href="http://www.sunshineheart.com/press-releases/sunshine-heart-announces-results-of-its-c-pulse-feasibility.html"/><author><name>Sunshine Heart</name></author><published>2011-11-07T16:25:58Z</published><updated>2011-11-07T16:25:58Z</updated><summary type="html" xml:lang="en-US"><![CDATA[Patients implanted with the C-Pulse Heart Assist System demonstrated statistically significant improvement based on New York Heart Association class reduction, Quality of Life and Left Ventricular]]></summary></entry><entry><title>Sunshine Heart’s Feasibility Trial Outcomes to Be Presented at Transcatheter Cardiovascular Therapeutics Conference</title><id>http://www.sunshineheart.com/press-releases/sunshine-hearts-feasibility-trial-outcomes-to-be-presented-a.html</id><link rel="alternate" type="text/html" href="http://www.sunshineheart.com/press-releases/sunshine-hearts-feasibility-trial-outcomes-to-be-presented-a.html"/><author><name>Sunshine Heart</name></author><published>2011-10-19T15:38:07Z</published><updated>2011-10-19T15:38:07Z</updated><summary type="html" xml:lang="en-US"><![CDATA[October 19, 2011: Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced that the C-Pulse Heart Assist System will be featured in two clinical presentations at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The TCT symposium, sponsored by the Cardiovascular Research Foundation, will take place November 7 through 11 in San Francisco, California.]]></summary></entry><entry><title>Sunshine Heart Completes Feasibility Study for Fully-Implantable C-Pulse® Heart Assist System</title><id>http://www.sunshineheart.com/press-releases/sunshine-heart-completes-feasibility-study-for-fully-implant.html</id><link rel="alternate" type="text/html" href="http://www.sunshineheart.com/press-releases/sunshine-heart-completes-feasibility-study-for-fully-implant.html"/><author><name>Sunshine Heart</name></author><published>2011-06-09T22:15:24Z</published><updated>2011-06-09T22:15:24Z</updated><summary type="html" xml:lang="en-US"><![CDATA[Sunshine Heart, Inc., a global medical device company focused on innovative technologies for Class III/ambulatory Class IV (moderate to severe) heart failure, today announced it has completed an initial animal study of a next-generation transcutaneous C-Pulse® Heart Assist System. The study, conducted at Texas Heart Institute in Houston, demonstrated that a combined driver and C-Pulse cuff implanted around the heart’s aorta can be successfully powered from a wireless, external battery unit. This fully-implantable C-Pulse model would eliminate the need for wires to breach the skin, thereby improving patient comfort and reducing the risk of infection.]]></summary></entry><entry><title>Sunshine for heart failure</title><id>http://www.sunshineheart.com/press-releases/sunshine-for-heart-failure.html</id><link rel="alternate" type="text/html" href="http://www.sunshineheart.com/press-releases/sunshine-for-heart-failure.html"/><author><name>Sunshine Heart</name></author><published>2011-05-19T15:45:59Z</published><updated>2011-05-19T15:45:59Z</updated><summary type="html" xml:lang="en-US"><![CDATA[Many a company has stumbled chasing the elusive dream of making an artificial heart or a small pump to provide some assistance to those  whose heart is failing.
 
Australia's Ventracor, which envisaged a pump to replace the crucial million left ventricle or chamber of the diseased heart , collapsed during the global financial crisis. As investors preferred to fund later stage businesses rather than riskier start-ups.
 
Now a second Australian company, Sunshine Heart, has re-emerged with plans to take its inherently less risky heart assist device into clinical trials.]]></summary></entry><entry><title>AAP Australian Business News</title><id>http://www.sunshineheart.com/press-releases/aap-australian-business-news.html</id><link rel="alternate" type="text/html" href="http://www.sunshineheart.com/press-releases/aap-australian-business-news.html"/><author><name>Sunshine Heart</name></author><published>2011-05-13T16:39:00Z</published><updated>2011-05-13T16:39:00Z</updated><summary type="html" xml:lang="en-US"><![CDATA[Sydney - Friday - May 13: SUNSHINE HEART (ASX:SHC) may have appreciated all the attention because the company provided one of the more complete responses to an ASX query we have seen recently, this time over a price rise from 4.9c on Tuesday to as high as 6.3c yesterday. The company offered several factors, the main one being that this week the company had been conducting an education roadshow with the CEO and a cardiac specialist from the US for institutional investors and members of the medical profession]]></summary></entry><entry><title>Sunshine Heart Announces Completion of Enrollment of 20 Patients for C-Pulse® Heart Assist System</title><id>http://www.sunshineheart.com/press-releases/sunshine-heart-announces-completion-of-enrollment-of-20-pati.html</id><link rel="alternate" type="text/html" href="http://www.sunshineheart.com/press-releases/sunshine-heart-announces-completion-of-enrollment-of-20-pati.html"/><author><name>Sunshine Heart</name></author><published>2011-04-04T15:10:01Z</published><updated>2011-04-04T15:10:01Z</updated><summary type="html" xml:lang="en-US"><![CDATA[Twenty Patients Successfully Implanted with Unique Heart Failure Treatment Device –

Minneapolis, MN, April 3, 2011 – Sunshine Heart, Inc., a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced that its C-Pulse® Heart Assist System has been implanted in 20 patients globally as of March 31, 2011. The C-Pulse studies are primarily designed to assess safety and provide indications of performance of this device in Class III/ambulatory Class IV (moderate to severe) heart failure patients suffering from symptoms such as shortness of breath and reduced mobility.]]></summary></entry><entry><title>Sunshine Heart Announces First Minimally Invasive Thoracotomy Procedures Performed for the C-Pulse Heart Assist System</title><id>http://www.sunshineheart.com/press-releases/sunshine-heart-announces-first-minimally-invasive-thoracotom.html</id><link rel="alternate" type="text/html" href="http://www.sunshineheart.com/press-releases/sunshine-heart-announces-first-minimally-invasive-thoracotom.html"/><author><name>Sunshine Heart</name></author><published>2010-08-31T18:17:00Z</published><updated>2010-08-31T18:17:00Z</updated><summary type="html" xml:lang="en-US"><![CDATA[First Minimally Invasive Thoracotomy Procedures Performed for the C-Pulse Heart Assist System]]></summary></entry><entry><title>Third implant at University of Alabama Birmingham Medical Centre</title><id>http://www.sunshineheart.com/press-releases/third-implant-at-university-of-alabama-birmingham-medical-ce.html</id><link rel="alternate" type="text/html" href="http://www.sunshineheart.com/press-releases/third-implant-at-university-of-alabama-birmingham-medical-ce.html"/><author><name>Sunshine Heart</name></author><published>2010-05-25T04:26:00Z</published><updated>2010-05-25T04:26:00Z</updated><summary type="html" xml:lang="en-US"><![CDATA[Third implant at University of Alabama Birmingham Medical Centre]]></summary></entry><entry><title>Second implant at University of Alabama Birmingham Medical Centre</title><id>http://www.sunshineheart.com/press-releases/second-implant-at-university-of-alabama-birmingham-medical-c.html</id><link rel="alternate" type="text/html" href="http://www.sunshineheart.com/press-releases/second-implant-at-university-of-alabama-birmingham-medical-c.html"/><author><name>Sunshine Heart</name></author><published>2010-05-19T04:24:00Z</published><updated>2010-05-19T04:24:00Z</updated><summary type="html" xml:lang="en-US"><![CDATA[Second implant at
University of Alabama Birmingham Medical Centre]]></summary></entry></feed>
